Follicular lymphoma:the diminishing role of chemotherapy
作者机构：IRCCS Azienda Ospedaliero-Universitaria di BolognaIstituto di Ematologia“Seràgnoli”Bologna 40138Italy Dipartimento di Medicina SpecialisticaDiagnostica e SperimentaleUniversitàdi BolognaBologna 40138Italy
出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)
年 卷 期：2022年第8卷第1期
页 面：393-411页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Follicular lymphoma POD24 target therapies chemo-immunotherapy biological heterogeneity
摘 要：Follicular lymphoma(FL)is the most common indolent non-Hodgkin lymphoma,accounting for 70%of cases in Western *** this unique name,FL is an extremely heterogeneous disease,both clinically and *** basis of FL heterogeneity lies in the different biological pathways which can be activated,because of the variety of gene mutations that can ***,there is a growing interest in the knowledge of these activated pathways,which is also testified by the presence of a new model that incorporates FL mutations to define patient’s prognosis(m7-FLIPI).These evaluations are also appealing because of the recent possibility of using“targeted therapies.Targeted therapies are new tools,currently applicable in the setting of relapse/refractory(R/R)disease,where we can find a great variety of“chemo-free*** in other hematologic malignancies,“cellular therapyenriches FL drug scenario,including T-cell dependent bispecific antibodies and chimeric antigen receptor(CAR)*** FL heterogeneity is the basis of the difference in therapeutic efficacy and disease course among patients,the hope for the future is to understand FL biology more deeply,to better comprehend how to obtain more representative samples and pre-treatment prognostic information in order to individualize the treatment strategy as early as frontline therapy.
维普期刊数据库